Add to ORKGBackground Platelet glycoprotein IIb/IIIa inhibitors have been shown to reduce cardiac complications in patients undergoing percutaneous coronary intervention. The clinical efficacy of these drugs in acute coronary syndromes, however, is still unclear. We did a meta-analysis of all large randomised trials designed to study the clinical efficacy and safety of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes who were not routinely scheduled to undergo early coronary revascularisation. Methods Inclusion criteria were: randomisation of patients with acute coronary syndromes but without persistent ST elevation; comparison of a glycoprotein IIb/IIIa inhibitor with placebo or control therapy; non-recommendation of early c...
BACKGROUND: There are limited contemporary data on the early use of clopidogrel or glycoprotein (Gp...
Background—The use of upstream small-molecule glycoprotein (GP) IIb/IIIa inhibitors in non–ST-segmen...
Aims. We investigate the effect of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors on long-term outco...
Background Platelet glycoprotein IIb/IIIa inhibitors have been shown to reduce cardiac complications...
It is still unknown whether upstream administration of glycoprotein (Gp) IIb/IIIa inhibitors, aiming...
ObjectivesThe purpose of this study was to investigate the efficacy and safety of glycoprotein IIb/I...
<p>The risk and benefit of GP-IIb/IIIa Inhibition (GPI) in combination with recent antiplatelet regi...
Background: Even though time-to-treatment has been shown to be a determinant of mortality in primary...
BACKGROUND: Glycoprotein (GP) IIb/IIIa receptor blockers prevent life-threatening cardiac com...
Background: Glycoprotein IIb/IIIa inhibitors (GPI) are still used in patients with ST-segment elevat...
Matthew A Silva1, Jennifer L Donovan1,3, Pritesh J Gandhi2, Gregory A Volturo31Massachusetts College...
Background Glycoprotein IIb/IIIa inhibitors (GPI) are still used in patients with ST-segment elevati...
Background Glycoprotein IIb/IIIa inhibitors (GPI) are still used in patients with ST-segment elevati...
Aims: To compare three glycoprotein IIb/IIIa receptor antagonists (GPIs) in terms of platelet inhibi...
AbstractDespite the success of abciximab in preventing ischemic events after percutaneous coronary i...
BACKGROUND: There are limited contemporary data on the early use of clopidogrel or glycoprotein (Gp...
Background—The use of upstream small-molecule glycoprotein (GP) IIb/IIIa inhibitors in non–ST-segmen...
Aims. We investigate the effect of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors on long-term outco...
Background Platelet glycoprotein IIb/IIIa inhibitors have been shown to reduce cardiac complications...
It is still unknown whether upstream administration of glycoprotein (Gp) IIb/IIIa inhibitors, aiming...
ObjectivesThe purpose of this study was to investigate the efficacy and safety of glycoprotein IIb/I...
<p>The risk and benefit of GP-IIb/IIIa Inhibition (GPI) in combination with recent antiplatelet regi...
Background: Even though time-to-treatment has been shown to be a determinant of mortality in primary...
BACKGROUND: Glycoprotein (GP) IIb/IIIa receptor blockers prevent life-threatening cardiac com...
Background: Glycoprotein IIb/IIIa inhibitors (GPI) are still used in patients with ST-segment elevat...
Matthew A Silva1, Jennifer L Donovan1,3, Pritesh J Gandhi2, Gregory A Volturo31Massachusetts College...
Background Glycoprotein IIb/IIIa inhibitors (GPI) are still used in patients with ST-segment elevati...
Background Glycoprotein IIb/IIIa inhibitors (GPI) are still used in patients with ST-segment elevati...
Aims: To compare three glycoprotein IIb/IIIa receptor antagonists (GPIs) in terms of platelet inhibi...
AbstractDespite the success of abciximab in preventing ischemic events after percutaneous coronary i...
BACKGROUND: There are limited contemporary data on the early use of clopidogrel or glycoprotein (Gp...
Background—The use of upstream small-molecule glycoprotein (GP) IIb/IIIa inhibitors in non–ST-segmen...
Aims. We investigate the effect of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors on long-term outco...